Unaudited Financial Results along with Limited Review Report for the Quarter ended on 30th June 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zenlabs Ethica, a single-segment pharma trading company based in Chandigarh, reported Q1 FY26 revenue from operations of Rs. 1,147.72 lakhs, down about 7.2% from Rs. 1,236.26 lakhs in the same quarter last year. Total income fell to Rs. 1,148.15 lakhs versus Rs. 1,236.54 lakhs YoY. Profit before tax dropped sharply to Rs. 4.45 lakhs from Rs. 7.16 lakhs, while profit after tax slipped to Rs. 3.33 lakhs from Rs. 4.18 lakhs, translating to an EPS of Rs. 0.05 (vs Rs. 0.06 YoY). The auditor (N Kumar Chhabra & Co.) issued an unmodified limited review opinion with no qualifications or emphasis of matter. The company also updated its insider trading and fair disclosure codes in line with SEBI's PIT Regulations.
Soft quarterly show with both top line and bottom line shrinking YoY, though margins compressed more than revenues, signalling pressure on profitability. Shares may react negatively given the weak YoY performance and very thin absolute earnings, though the company remains profitable and the auditor's report is clean.